Prevymis® (letermovir) – Updated label
August 2, 2023 - The FDA approved an update to the drug label for Merck’s Prevymis (letermovir), to allow for extension of the dosing regimen from 100 to 200 days post-transplant for the prophylaxis of cytomegalovirus (CMV) infection and disease in adult CMV seropositive recipients (R+) of an allogeneic hematopoietic stem cell transplant (HSCT) who are at risk for late CMV infection and disease.
Top